Evidence map›Paper›PMID 24941376›Full record

ReviewCritical reviews in oncogenesis2014

NK cells in the tumor microenvironment.

Stine K Larsen, Yanhua Gao, Per H Basse

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Critical reviews in oncogenesis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04616235 (Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade - a Randomized Controlled Trial), which is not on this map. Cited by 80 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04616235 nacompletednot on this mapstarted 2021, after this paper: background citation

Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade - a Randomized Controlled Trial

TypeinterventionalSponsorRigshospitalet, DenmarkRan2021 to 2021Enrolled30ConditionsInterleukin-6 Inhibition, Physical Stress, Appetitive BehaviorArmsTocilizumab Injectable Product, Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. From bench to bedside: the past, present and future of IL-21 immunotherapy.Medical oncology (Northwood, London, England) · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Transcriptional signature of CD56Frontiers in immunology · 2024
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stine K LarsenUniversity of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh PA 15213, USA; Department of Hematology, 54P4, Copenhagen University Hospital, Herlev, Denmark.
Yanhua GaoDepartment of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15224, USA.
Per H BasseUniversity of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh PA 15213, USA; Department of Immunology, University of Pittsburgh, Pittsburgh PA 15213, USA.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904NCI NIH HHS P30CA047904
6 · The paper itself

Abstract

The presence of natural killer (NK) cells in the tumor microenvironment correlates with outcome in a variety of cancers. However, the role of intratumoral NK cells is unclear. Preclinical studies have shown that, while NK cells efficiently kill circulating tumor cells of almost any origin, they seem to have very little effect against the same type of tumor cells when these have extravasated. The ability to kill extravasated tumor cells is, however, is dependent of the level of activation of the NK cells, as more recent published and unpublished studies, discussed below, have demonstrated that interleukin-2-activated NK cells are able to attack well-established solid tumors.

Indexed as

Tumor MicroenvironmentHumansKiller Cells, NaturalNeoplasmsPrognosis

Identifiers

PMID24941376
PMCPMC4062922

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.